Paradigm Biocapital Advisors LP
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1855655
NEW YORK, NY
Position in ALNY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$144,494,400
New position
Shares Held
480,000
first reported quarter
Ownership
0.359%
of shares outstanding
% of Portfolio
3.14%
of 13F equity value
Holder Rank
#43
of 784 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Paradigm Biocapital Advisors LP holds $4,608,890,546 across 28 Biotechnology names. ALNY ranks #11 (3.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
6,361,323 | $1,191,348,571 | |
| 2 | EWTX |
Edgewise Therapeutics, Inc.
|
10,215,455 | $415,053,936 | |
| 3 | GMAB |
Genmab A/S
|
13,133,131 | $360,767,108 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
3,840,778 | $340,984,270 | |
| 5 | APGE |
Apogee Therapeutics, Inc.
|
1,576,385 | $209,233,581 | |
| 6 | ORKA |
Oruka Therapeutics, Inc.
|
2,144,526 | $204,094,539 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
6,357,523 | $198,736,168 | |
| 8 | BLTE |
Belite Bio, Inc
|
1,232,877 | $189,844,564 |
All Filings in ALNY
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $144,494,400 | 480,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||